# A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

> **NCT04047290** · PHASE1 · COMPLETED · sponsor: **Akesobio Australia Pty Ltd** · enrollment: 80 (actual)

## Conditions studied

- Neoplasms Malignant

## Interventions

- **DRUG:** AK112

## Key facts

- **NCT ID:** NCT04047290
- **Lead sponsor:** Akesobio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-20
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-02-27
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047290, "A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04047290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*